Emerald Advisers LLC Sells 19,907 Shares of Guardant Health, Inc. $GH

Emerald Advisers LLC trimmed its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 2.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 841,917 shares of the company’s stock after selling 19,907 shares during the quarter. Guardant Health comprises about 2.5% of Emerald Advisers LLC’s investment portfolio, making the stock its 2nd largest holding. Emerald Advisers LLC’s holdings in Guardant Health were worth $77,768,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Guardant Health by 14.9% in the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after buying an additional 435,232 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after buying an additional 277,001 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in shares of Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after buying an additional 72,162 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $158.40 on Tuesday. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08. The company has a market cap of $21.00 billion, a P/E ratio of -46.73 and a beta of 1.59. The firm has a 50 day simple moving average of $128.92 and a two-hundred day simple moving average of $108.75.

Analyst Upgrades and Downgrades

GH has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Morgan Stanley lifted their price objective on Guardant Health from $130.00 to $175.00 and gave the company an “overweight” rating in a report on Thursday. Royal Bank Of Canada began coverage on Guardant Health in a research report on Thursday, June 11th. They set an “outperform” rating and a $185.00 target price for the company. The Goldman Sachs Group initiated coverage on Guardant Health in a report on Friday, June 5th. They set a “buy” rating and a $165.00 target price on the stock. Finally, Mizuho raised their price target on Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus target price of $155.70.

Insider Transactions at Guardant Health

In other news, Director Myrtle S. Potter sold 1,556 shares of Guardant Health stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $204,084.96. Following the transaction, the director owned 20,971 shares in the company, valued at approximately $2,750,556.36. This trade represents a 6.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the transaction, the chief executive officer directly owned 1,881,336 shares of the company’s stock, valued at $285,097,657.44. This trade represents a 7.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 708,681 shares of company stock worth $90,566,438. 5.60% of the stock is owned by insiders.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.